CHEMBRIDGE CORPORATION

Advancing Research in Drug Discovery and Chemical Biology

Leveraging Small Molecule Libraries in Cancer Research

More than 1,500 articles cite the use of ChemBridge® small molecule screening libraries and compounds in a wide variety of research areas using high-throughput screening or focused screening following computer-aided screening.

The list below highlights a small sampling of articles from 2014 and 2015 to present that focus on work in cancer research and provides a sample of the different techniques employed and targets explored in hit finding and probe discovery using ChemBridge libraries and compounds. For a complete list of publications, contact **sales@chembridge.com**.

Please check back for updates, as this list will be expanded with additional examples.

- **Identification of a Selective G1- Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks**

  Bilsland AE, et al.; Neoplasia. 2015 Sep;17(9):704-15.

  The authors identified CB-20903630 (ChemBridge ID 20903630) as a senescence associated beta-galactosidase inhibitor using virtual screening as the primary screen.

- **Estrogen receptor alpha inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression**

  Andruska ND, et al.; Proc Natl Acad Sci U S A. 2015 Apr 14;112 (15): 4737.42.

  The authors identified BHPI (ChemBridge ID 6373538) as an estrogen receptor alpha biomodulator using a high-throughput screen as the primary screen.

- **A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia**

  Kim DJ, et al.; Mol Cells. 2015 Apr;38(4):373-9.

  The authors identified PA-12 (ChemBridge ID 7871820) as pyruvate kinase M2 activator using a virtual screen as the primary screen.

- **Anticancer/Antiviral Agent Akt Inhibitor-IV Massively Accumulates in Mitochondria and Potently Disrupts Cellular Bioenergetics**

  Meinig JM and Peterson BR.; ACS Chem Biol. 2015 Feb 20;10(2):570-6.

  The authors had previously identified AKTIV (Akt Inhibitor-IV; ChemBridge ID 5233705) as a PI3-kinase/Akt (protein kinase B) inhibitor and focused on elucidation of the mechanism of action.

- **Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis**

  Tang X, et al.; Oncotarget. 2014 Mar 15;5(5):1352-62.

  The authors had previously identified HepIN-13 (ChemBridge ID 5717483) as serine protease Hepsin inhibitor and focused on the development, analysis and animal trial of the inhibitor.

- **Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model**

  Borriello L et al.; Cancer Lett. 2014 Jul 28;349(2):120-7.

  The authors identified Compound 1 (ChemBridge ID 7967674) as a neuropilins (non-tyrosine kinase receptor) antagonist using a virtual screen as the primary screen.

- **Activation of the Proapoptotic Bcl-2 Protein Bax by a Small Molecule Induces Tumor Cell Apoptosis**

  Zhao G et al.; Mol Cell Biol. 2014 Apr;34(7):1198-207.

  The authors identified Compound 106 (ChemBridge ID 78872106) as a proapoptotic Bcl-2 protein Bax activator using a virtual screen as the primary screen.

- **Discovery of SIRT3 Inhibitors Using SAMDI Mass Spectrometry**

  Patel K et al.; J Biomol Screen. 2015 Aug;20(7):842-8.

  The authors identified SDX-437 (ChemBridge ID 7706915) as a sirtuin deacytelase 3 (SIRT3) inhibitor using a high-throughput screen.

ChemBridge Corporation
San Diego, CA, USA
www.chembridge.com

Phone +1.858.451.7400
Fax +1.858.451.7401
E-mail **sales@chembridge.com**

Rev. 20160715